On 14 May 2025, the International Patient Organisation for Primary Immunodeficiencies (IPOPI) organised a PID Forum titled ‘Shaping the Future of Research: Patients as Equal Partners’. The event took place in Brussels (Belgium) in the European Parliament. It was co-hosted by Member of the European Parliament (MEP) Romana Jerković (S&D, Croatia) and Nicolás González Casares (S&D, Spain).

Martine Pergent, President of IPOPI, moderated the Forum, which aimed at discussing how EU research could benefit from the inclusion and recognition of patient organisations as equal partners.

The speakers of the Forum were the following:

• MEP Romana Jerkovic (S&D, Croatia) opened the Forum by highlighting the importance of patients in advancing health research, as experts in understanding rare diseases, research and the complex care pathways.
• MEP Nicolás González Casares (S&D, Spain) supported the crucial participation of patients with rare diseases in research, as they are the key to advancing rare disease research. MEP González Casares also highlighted the value of newborn screening as a tool to overcome certain rare diseases early in life.
• Johan Prevot, IPOPI Executive Director, highlighted how patients and patient organisations are key players who contribute to ensuring that research can most effectively tackle current unmet needs and that it is fit for purpose. Supranational federations representing specific rare diseases, such as IPOPI, are key players in many research and innovative projects.
• Dr Daria Julkowska, Coordinator at the European Rare Diseases Research Alliance (ERDERA), emphasised the importance of patient involvement in rare disease research and also listed a number of challenges that still need to be addressed within the funding programme.
• Dr Frank Staal, Recombination Coordinator working at Leiden University Medical Center (the Netherlands), spoke about the value of collaborating with patient organisations for EU funded research projects and spoke about his experience in collaborating with IPOPI on the RECOMB project and the success achieved thanks to their involvement in a series of research projects in the field of PIDs.
• Dr Filomeen Haerynck, Paediatric Immunologist at UZ Gent (Belgium), commented on the growing impact of patients’ and patient organisations’ involvement in research over the years.
• Christina Kyriakopoulou, Scientific Policy Officer at DG RTD.D.2 of the European Commission, emphasised that no European country could solve the issue of rare diseases alone and that thinking out of the box, flexibility and cooperation between innovators and patient communities were crucial to health research.

The Forum drew a large audience, including delegates from various NMOs: Janine Bastiaans (Board member of the Dutch PID patient organisations), David Jimenez (Board member of the Spanish PID patient organisation, AEDIP) and Marie-Sophie Enry-Aude (Board member of the French PID patient organisation, IRIS).

IPOPI would like to thank CSL Behring, Grifols and Takeda for their continued support.

The report will shortly be available here: https://ipopi.org/our-work/early-diagnosis-and-care/

The Platform of Plasma Users (PLUS) organised its Stakeholder Consensus Conference on January 23-24 in Estoril (Portugal).

The meeting gathered representatives from the following stakeholder organisations: Alpha-1 Belgium, the American Platform of Plasma Users (A-PLUS), the European Blood Alliance (EBA), the European Haemophilia Consortium (EHC), the European Plasma Alliance (EPA), the GBS-CIDP Foundation International, the International Patient Organisation for Primary Immunodeficiencies (IPOPI), the International Plasma and Fractionation Association (IPFA), European Blood Alliance (EBA), Plasma Protein Therapeutics Association (PPTA), World Federation of Haemophilia (WFH),  Marketing Research Bureau (MRB) and Thomas Kluszczynski (ACESO Healthcare Consulting).

During the two-day conference, participants discussed  current priority topics, including:

• An overview of the latest worldwide plasma and plasma-derived medicinal products supply situation;
• The role of the Critical Medicines Alliance in Europe and the procurement and supply of PDMPs;
• Stockpiling in the EU and how this could be applied for PDMPs;
• The ongoing implementation of the regulation on substances of human origin (SoHO) and the current discussions around the pharma legislation;
• The importance of ensuring the safety and efficacy of plasma-derived medicines worldwide.

Several elements were identified as shared interests during the discussions, and participants agreed to continue collaborating on that basis. As a result, some organisations agreed to a joint statement on the safety of PDMPs and to further discussions on the developments of the Critical Medicines Alliance from a plasma-derived medicines perspective